ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?

Key Takeaways ANIP is seeing sharp rare-disease growth driven by Cortrophin Gel and steady generics performance.Cortrophin Gel sales are up 70% YTD and projected to rise 75-78% for 2025, offsetting softness elsewhere.AMRX benefits from diversified segments, though generics pricing pressure and mixed specialty trends persist.ANI Pharmaceuticals (ANIP) and Amneal Pharmaceuticals (AMRX) are both generic drugmakers, but their overall business models differ.ANIP’s operations are split between rare disease therap ...